StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
011040.KQ$4970.00-1.97%
Fair $4970.00+0.0%

011040.KQ

Kyung Dong Pharmaceutical Co., Ltd.

Unknown / UnknownKOSDAQ

$4970.00

-100.00 (-1.97%)

Fairly Valued+0.0%Fair Value $4970.00Fund rank 27/100 · Data gapFallback financials|
SA 34/D
F-Score: 6/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $-8.5B · quality 62.0/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 26/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

34/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 3.7%, below the 5% threshold
Thesis & Journal · 011040.KQLocal privado en este navegador · Kyung Dong Pharmaceutical Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$134.0B

P/E

15.8x

↑

EV/EBITDA

10.2x

↑

ROE

3.7%

↑

Gross Margin

59.7%

↑

Debt/Equity

0.20

↓
52-Week Range$4970
$4900$6890

TradingView lightweight chart

011040.KQ price, volumen y niveles de valoración

Último $4,970Periodo -24.4%
Fair value: $4,970

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+2.4%

FCF CAGR

—

FCF margin

-1.8%

FCF / Net income

-0.42x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $196.27B · net income $8.53B · FCF $-3.58B

2022-FY → 2025-FY

Gross margin

59.7%+7.1% pts

Operating margin

3.9%-0.6% pts

Net margin

4.3%-2.3% pts

FCF margin

-1.8%+5.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$196.27B$196.27B$193.94B$162.67B$182.72B
Net Income$8.53B$8.53B$5.47B$-20.71B$12.16B
EBITDA$14.58B$14.58B$12.80B$-11.06B$25.51B
EPS315.00315.00203.00-763.00447.00
Gross Margin59.7%59.7%59.0%55.0%52.6%
Operating Margin3.9%3.9%1.4%-15.3%4.5%
Net Margin4.3%4.3%2.8%-12.7%6.7%
Balance Sheet
Debt/Equity0.200.200.180.070.10
Cash Flow
Free Cash Flow$-3.58B$-3.58B$-19.84B$-8.53B$-12.77B
Returns
ROE3.7%3.7%2.5%-9.1%4.7%
Valuation
P/E15.7815.7830.69—16.98
EV/EBITDA10.1710.1714.90—8.58
P/B0.590.590.760.780.80
Growth & Yield
Revenue Growth1.2%1.2%19.2%-11.0%—
EPS Growth55.2%55.2%126.6%-270.7%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

11.9%

razonable

EPS terminal req.

$441.00

Spread vs growth

43.3%

5Y implied EPS CAGR

11.1%

razonable

EPS terminal req.

$533.62

Spread vs growth

44.1%

10Y implied EPS CAGR

10.6%

razonable

EPS terminal req.

$859.39

Spread vs growth

44.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -15.2%

Total return

-15.2%

Start / end P/E

28.9x → 15.8x

EPS bridge

203.00 → 315.00

Residual

-25.0%

EPS growth+55.2%
Multiple rerating-45.3%
Dividend+0.0%
Residual / FX / buybacks / cross-term-25.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.